Form 4: Vir Biotechnology Director Jeffrey Hatfield Boosts Stake with RSU and Stock Option Grants

Jeffrey S. Hatfield, a Director at Vir Biotechnology, Inc., has acquired 8,000 restricted stock units and 16,000 stock options, increasing his beneficial ownership in the company.

Summary

• Jeffrey S. Hatfield, a Director of Vir Biotechnology, Inc. (VIR), acquired 8,000 shares of Common Stock in the form of Restricted Stock Units (RSUs) on May 30, 2025, at a price of $0.
• These 8,000 RSUs are part of the Issuer's Equity Incentive Plan and are scheduled to vest in full on May 30, 2026.
• Following this transaction, Mr. Hatfield beneficially owns 31,806 shares of Common Stock directly.
• Additionally, Mr. Hatfield acquired 16,000 stock options (right to buy) on May 30, 2025, with an exercise price of $4.94 per share.
• These 16,000 stock options will vest and become exercisable in full on May 30, 2026, and have an expiration date of May 29, 2035.
• After this transaction, Mr. Hatfield beneficially owns 16,000 derivative securities (stock options) directly.
• A Power of Attorney, dated March 12, 2025, grants authority to specific individuals to execute and file SEC forms on behalf of Mr. Hatfield.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director is increasing their stake in the company through equity awards, aligning their interests with shareholders. This is a routine and expected transaction, reflecting standard compensation practices.

Positives

• The acquisition of restricted stock units and stock options by a director indicates continued alignment of management's interests with shareholders.
• The grants are part of the Issuer's Equity Incentive Plan, suggesting a standard compensation practice aimed at retaining and incentivizing key personnel.

Future Outlook

The document primarily details past and future vesting schedules for equity awards, indicating a commitment to long-term incentives for the director. The vesting of RSUs and stock options on May 30, 2026, represents a future milestone for the director's equity holdings.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all publicly traded companies, including those in the biotechnology sector. It reflects standard equity compensation practices used to align the interests of directors and executives with shareholders, a common strategy in high-growth, research-intensive industries like biotech.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options as part of executive and director compensation is a standard practice across the biotechnology and broader corporate landscape, comparable to compensation structures seen at companies like Moderna, Pfizer, or Gilead Sciences.
• The vesting schedule, with full vesting occurring approximately one year after the grant date, is a common approach to incentivize retention and long-term performance, aligning with typical industry benchmarks for equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: The acquisition of equity awards by a director can be viewed positively as it aligns the director's financial interests with the long-term performance of the company, potentially signaling confidence in future growth.
• Employees: The equity incentive plan, under which these awards were granted, is a common tool for employee and director retention and motivation, which can positively impact morale and commitment.

Next Steps

• The 8,000 Restricted Stock Units are expected to vest in full on May 30, 2026.
• The 16,000 Stock Options are expected to vest and become exercisable in full on May 30, 2026.

Key Dates

Recommendation

Keywords

Vir Biotechnology, VIR, Jeffrey S. Hatfield, Form 4, SEC filing, Restricted Stock Units, RSUs, Stock Options, Equity Incentive Plan, Director compensation, Insider ownership, Biotechnology